A PHASE III OPEN-LABEL STUDY OF THE EFFICACY AND SAFETY OF ARD-0403
ARD-0403 功效和安全性的 III 期开放标签研究
基本信息
- 批准号:7952253
- 负责人:
- 金额:$ 13.12万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2008
- 资助国家:美国
- 起止时间:2008-12-01 至 2009-11-30
- 项目状态:已结题
- 来源:
- 关键词:Adverse eventAndrogensBiochemistryClinicalClinical ResearchComputer Retrieval of Information on Scientific Projects DatabaseDataDoseElectrocardiogramEnrollmentFundingGrantHematologyHormonesInformed ConsentInstitutionLaboratoriesMaintenancePatientsPharmaceutical PreparationsPhasePhysical ExaminationProcessProstateReactionResearchResearch PersonnelResourcesSafetySerious Adverse EventSerumSiteSourceTestosteroneTitrationsUnited States National Institutes of Healthdigitalmenopen labelrectalsafety studytreatment duration
项目摘要
This subproject is one of many research subprojects utilizing the
resources provided by a Center grant funded by NIH/NCRR. The subproject and
investigator (PI) may have received primary funding from another NIH source,
and thus could be represented in other CRISP entries. The institution listed is
for the Center, which is not necessarily the institution for the investigator.
This is a phase III, open-label, dose-titration, multi-center study. Titration is defined as the process of gradually adjusting the dose of a medication until the desired effect is achieved.
Up to 150 testosterone deficient men are expected to enter this study. Each of them will receive 28 daily applications of 2.25g ARD-0403. After 28 days of treatment, if testosterone levels are not within the reference 300- 700 ng/dL), the dose of ARD-0403 will be titrated, if serum testosterone levels are below 300 ng/dl, the dose will be increased by 2.25g to 4.5g and if the level is above 700 ng/dl, the dose will be decreased to 1.5 g. Further dose titrations may be made prior to patients entering a 12 week maintenance phase.
Prior to participation in the study, potential subjects will undergo an "inclusion phase" to determine whether they are eligible for the study. This phase will include the informed consent process, washout of current androgen treatment (if applicable), physical examination (including a digital rectal exam to check prostate size), an electrocardiogram (ECG), safety laboratory assessments (consisting of PSA, hematology, and serum hormone levels). Subjects need to have documented serum total testosterone levels <250ng/dL on at least two occasions prior to enrolling into the study.
Safety of the study drug will be assessed by evaluating the collected safety data of adverse events, serious adverse events (SAEs), ECG, vital signs, application site reactions and clinical laboratory parameters (biochemistry and hematology).
这个子项目是许多研究子项目中的一个
由NIH/NCRR资助的中心赠款提供的资源。子项目和
研究者(PI)可能从另一个NIH来源获得了主要资金,
因此可以在其他CRISP条目中表示。所列机构为
研究中心,而研究中心不一定是研究者所在的机构。
这是一项III期、开放标签、剂量滴定、多中心研究。 滴定被定义为逐渐调整药物剂量直至达到预期效果的过程。
预计将有多达150名睾酮缺乏的男性参加这项研究。 他们每人每天将接受28次2.25 g ARD-0403的应用。 治疗28天后,如果睾酮水平不在参考范围内(300- 700 ng/dL),则将滴定ARD-0403的剂量,如果血清睾酮水平低于300 ng/dl,则将剂量增加2.25 g至4.5 g,如果水平高于700 ng/dl,则将剂量降低至1.5 g。 在患者进入12周维持期之前,可以进行进一步的剂量滴定。
在参与研究之前,潜在受试者将经历“入选阶段”,以确定他们是否有资格参与研究。该阶段将包括知情同意过程、当前雄激素治疗的洗脱(如适用)、体格检查(包括直肠指检以检查前列腺大小)、心电图(ECG)、安全性实验室评估(包括PSA、血液学和血清激素水平)。 受试者需要在入组研究之前至少两次记录血清总睾酮水平<250 ng/dL。
将通过评价收集的不良事件、严重不良事件(SAE)、ECG、生命体征、给药部位反应和临床实验室参数(生化和血液学)的安全性数据来评估研究药物的安全性。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
RONALD Sherwin SWERDLOFF其他文献
RONALD Sherwin SWERDLOFF的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('RONALD Sherwin SWERDLOFF', 18)}}的其他基金
Diet and Exercise Modulate the Sperm Epigenome in Men
饮食和运动调节男性精子表观基因组
- 批准号:
10260434 - 财政年份:2019
- 资助金额:
$ 13.12万 - 项目类别:
Diet and Exercise Modulate the Sperm Epigenome in Men
饮食和运动调节男性精子表观基因组
- 批准号:
10018076 - 财政年份:2019
- 资助金额:
$ 13.12万 - 项目类别:
Diet and Exercise Modulate the Sperm Epigenome in Men
饮食和运动调节男性精子表观基因组
- 批准号:
10615591 - 财政年份:2019
- 资助金额:
$ 13.12万 - 项目类别:
PHASE II STUDY OF THE EFFECT OF FOOD WITH VARIOUS LEVELS OF FAT ON THE PHARMACOK
不同脂肪水平的食物对 PHARMACOK 影响的第二阶段研究
- 批准号:
8174527 - 财政年份:2009
- 资助金额:
$ 13.12万 - 项目类别:
PHASE IIA, PILOT, PHARMACOKINETIC STUDY OF ORAL TESTOSTERONE ESTER FORMULATIO
口服睾酮酯制剂的 IIA 期试验药代动力学研究
- 批准号:
7952260 - 财政年份:2008
- 资助金额:
$ 13.12万 - 项目类别:
A PHASE I, RANDOMIZED, OPEN-LABEL, CROSS-OVER STUDY TO INVESTIGATE POTENTIAL
旨在调查潜力的第一阶段随机、开放标签交叉研究
- 批准号:
7952256 - 财政年份:2008
- 资助金额:
$ 13.12万 - 项目类别:
A PHASE III, RANDOMIZED, MULTI-CENTER, OPEN-LABEL, FOLLOW-ON STUDY FOR LONG T
III 期、随机、多中心、开放标签、长期跟踪研究
- 批准号:
7952264 - 财政年份:2008
- 资助金额:
$ 13.12万 - 项目类别:
CLINICAL TRIAL: PHASE IIA, REPEAT DOSE, PHARMACOKINETIC STUDY OF ORAL TESTOSTERO
临床试验:IIA 期、重复剂量、口服睾酮的药代动力学研究
- 批准号:
7952270 - 财政年份:2008
- 资助金额:
$ 13.12万 - 项目类别:
A PHASE II, PLACEBO-CONTROLLED, DOUBLE-BLIND, DOSE-RANGING (35MG/D OR 70MG/D)
A 期、安慰剂对照、双盲、剂量范围(35MG/D 或 70MG/D)
- 批准号:
7606180 - 财政年份:2007
- 资助金额:
$ 13.12万 - 项目类别:
PHASE I, PILOT, PHARMACOKINETIC STUDY OF AN ORAL TESTOSTERONE PALMITATE FORMU
口服睾酮棕榈酸酯形式的 I 期试验药代动力学研究
- 批准号:
7606191 - 财政年份:2007
- 资助金额:
$ 13.12万 - 项目类别:
相似海外基金
Abnormalities in androgens and ovarian markers in reproductive-age racially and ethnically diverse women in a prospective longitudinal cohort
前瞻性纵向队列中不同种族和民族的育龄女性雄激素和卵巢标志物的异常
- 批准号:
10930196 - 财政年份:2023
- 资助金额:
$ 13.12万 - 项目类别:
Nonalcoholic Fatty Liver Disease (NAFLD) in Polycystic Ovary Syndrome: The Role of Androgens on Liver Injury and NAFLD Progression
多囊卵巢综合征中的非酒精性脂肪肝 (NAFLD):雄激素在肝损伤和 NAFLD 进展中的作用
- 批准号:
10735807 - 财政年份:2023
- 资助金额:
$ 13.12万 - 项目类别:
Sexual Differentiation of the Brain and Behaviour: Central and Peripheral Targets of Androgens
大脑和行为的性别分化:雄激素的中枢和外周目标
- 批准号:
RGPIN-2019-04999 - 财政年份:2022
- 资助金额:
$ 13.12万 - 项目类别:
Discovery Grants Program - Individual
Elucidation of the mechanisms by which cells recognize and respond to different levels of androgens
阐明细胞识别和响应不同水平雄激素的机制
- 批准号:
10418461 - 财政年份:2022
- 资助金额:
$ 13.12万 - 项目类别:
Influence of Androgens on Tissue-Specific Lipid Metabolites and Liver Injury in Young Women with NAFLD
雄激素对患有 NAFLD 的年轻女性组织特异性脂质代谢和肝损伤的影响
- 批准号:
10570208 - 财政年份:2022
- 资助金额:
$ 13.12万 - 项目类别:
Influence of Androgens on Tissue-Specific Lipid Metabolites and Liver Injury in Young Women with NAFLD
雄激素对患有 NAFLD 的年轻女性组织特异性脂质代谢和肝损伤的影响
- 批准号:
10355174 - 财政年份:2022
- 资助金额:
$ 13.12万 - 项目类别:
Paxillin and Androgens in the Regulation of Ovarian Follicle Development
桩蛋白和雄激素在卵巢卵泡发育调节中的作用
- 批准号:
10688086 - 财政年份:2022
- 资助金额:
$ 13.12万 - 项目类别:
Defining the impact of androgens on uterine immune cell function during endometrial tissue repair
确定子宫内膜组织修复过程中雄激素对子宫免疫细胞功能的影响
- 批准号:
2744296 - 财政年份:2022
- 资助金额:
$ 13.12万 - 项目类别:
Studentship
Use of novel 11-oxygenated androgens to improve diagnostic accuracy and therapeutics in polycystic ovary syndrome
使用新型 11-含氧雄激素提高多囊卵巢综合征的诊断准确性和治疗效果
- 批准号:
10431620 - 财政年份:2022
- 资助金额:
$ 13.12万 - 项目类别:
Paxillin and Androgens in the Regulation of Ovarian Follicle Development
桩蛋白和雄激素在卵巢卵泡发育调节中的作用
- 批准号:
10525097 - 财政年份:2022
- 资助金额:
$ 13.12万 - 项目类别: